According to research presented by Justin Watts, MD, at the 2024 ASH Annual Meeting & Exposition in San Diego, California, INCB057643 may improve patient outcomes in the treatment of hematologic malignancies including myelofibrosis.
The past year has been marked by exceptional achievements and inspiring moments, many captured by our photographers. We’ve collected pictures and stories from throughout 2024.
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.
Becker’s Healthcare is proud to spotlight 36 trailblazing chief innovation officers from hospitals and health systems across the nation.
A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
